Extracorporeal elimination of circulating pegylated liposomal doxorubicin (PLD) to enhance the benefit of cytostatic therapy in platinum-resistant ovarian cancer patients

Abstrakt

Ovarian cancer is the fifth most common malignancy in the world 's female population and with the highest lethality index among gynecological tumors. The prognosis of metastatic disease is usually poor, especially in platinum-resistant cases.

This article intends to review PLD characteristics and the importance of extracorporeal elimianiton to enhance treatment tolerance and benefits.

Klíčová slova

• pegylated liposomal doxorubicin
• palmar-plantar erythrodysesthesia
• rheopheresis
• toxicity